Quantcast

Industry news that matters to you.  Learn more

Shrink Wrap Used to Enhance Detection of Infectious Disease Biomarkers

Detecting HIV/AIDS, tuberculosis, malaria and other deadly infectious diseases as early as possible helps to prevent their rapid spread and allows for more effective treatments. But current detection methods are cost-prohibitive in most areas of the world. Now a new nanotechnology method—employing common, everyday shrink wrap—may make highly sensitive, extremely low-cost diagnosis of infectious disease agents possible.

SAP and BC Centre for Excellence in HIV/AIDS Pioneer New Technology, Redefine Treatment

The British Columbia Centre for Excellence in HIV/AIDS at St. Paul’s Hospital is pioneering new technology from PHEMI Health Systems and SAP AG (NYSE: SAP) to accelerate the treatment and improve the outcome for patients diagnosed with HIV/AIDS. The Centre intends to roll out powerful Big Data technology in a pilot project to deliver personalized medicine based on the genetic signature of the virus that infects each patient.

Gentris Corporation Launches Next Generation Human Transcriptome Array

Gentris Corporation (www.gentris.com), a global leader in pharmacogenomics and biorepository solutions, recently announced that it is expanding its genomic biomarker offering with the launch of Affymetrix GeneChip(R) Human Transcriptome Array (HTA) services. The GeneChip(R) HTA is a high resolution microarray for gene expression that is designed to empower next-generation expression profiling studies. The new array goes beyond gene-level expression profiling by providing the coverage and accuracy required to detect all known transcript isoforms produced by a gene.

Atherotech Diagnostics Lab Expands Heart Disease Atherotech Diagnostics Lab Expands Heart Disease Risk Assessment with AspirinWorks® Test

Atherotech Diagnostics Lab, a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions, recently launched the AspirinWorks® Test to complement its menu of cardiovascular disease risk assessment tests.

More than 1 million Americans experience new or recurrent heart attacks each year. These at-risk individuals are candidates for aspirin therapy and should be tested for the presence or absence of the therapy’s effect. The AspirinWorks Test is used to determine levels of 11‑Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids a physician in the determination of aspirin effect.

“The AspirinWorks Test maximizes the value of our VAP Lipid Panel and accompanying line of cardiometabolic disease diagnostics and management tests,” Atherotech CEO Michael Mullen said. “This offering is strategically aligned with our company’s mission to proactively manage risk and guide therapy to help improve patient outcomes.”

Aspirin therapy works on blood platelets to decrease levels of thromboxane A2 (TxA2), a powerful stimulator of platelet aggregation. Lower thromboxane levels and decreased platelet aggregation means less chance of developing a blood clot, and therefore, less chance of a heart attack or stroke. However, studies have shown that for several reasons, up to 25 percent of individuals do not get the expected beneficial effect of aspirin.

The AspirinWorks Test identifies those individuals who have elevated thromboxane levels despite taking a daily aspirin dose.

“The added information from the AspirinWorks Test will help provide a more accurate and complete evaluation of a patient’s cardiovascular health,” Atherotech Chief Medical Officer Michael Cobble, M.D., said. “Assessment of the chemical marker for platelet aggregation facilitates a strategic, scientifically validated approach to maximizing the value of aspirin therapy and minimizing the risk of heart attack and stroke.”

The AspirinWorks Test has been clinically validated through extensive research and numerous well-designed and well-powered clinical trials. The AspirinWorks Test is FDA cleared and used to test and guide treatment for hundreds of thousands of patients each year worldwide.

Atherotech provides a full complement of more than 60 routine and specialty diagnostic tests, including its patented VAP® Lipid Panel to help physicians establish the most effective course of treatment from a single source.

Source: Atherotech Diagnostics

PrimeraDx to Co-Develop Companion Diagnostics with Quest Diagnostics

PrimeraDx, Inc., a molecular diagnostics company, recently announced it has formed a non-exclusive diagnostics co-development agreement with Quest Diagnostics (NYSE: DGX), the world’s leading diagnostics information services company. The intent of the collaboration is to co-develop and commercialize molecular diagnostic products and services with a focus on supporting clinical development of targeted therapeutics for drug developers.